Immatics NV's lead asset, IMA203, shows promising early efficacy in melanoma, including difficult-to-treat uveal melanoma, per updated ASCO data. The company remains well-capitalized, with sufficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback